Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850149 | 0.93 | HSD17B10 (0.42) | P2RX7GPR119ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3851048 | 0.93 | P2RX7 (0.39) | P2RX7BCHEACHEBACE1ALDH1A1 | |
| SCHEMBL3851899 | 0.88 | P2RX7 (0.38) | P2RX7GPR119ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6461059 | 0.86 | ADRB2 (0.35) | P2RX7GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL5189897 | 0.85 | HSD17B10 (0.45) | P2RX7ALDH1A1SMN1; SMN2KMT2ACYP3A4 | |
| SCHEMBL3849629 | 0.82 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL5608783 | 0.82 | ITGA4 (0.35) | P2RX7 | |
| SCHEMBL3852759 | 0.82 | P2RX7 (0.37) | P2RX7ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL6632031 | 0.81 | BCHE (0.37) | GPR119BCHEACHEBACE1ALDH1A1 | |
| SCHEMBL3853158 | 0.81 | P2RX7 (0.39) | P2RX7ALDH1A1SMN1; SMN2KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | claimed |
| JP-2007526230-A | — | — | 2007-09-13 | — | — | JP | claimed |
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN MA INC. | 2005-09-29 | — | — | US | claimed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | claimed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| EP-1452532-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-1000051-B1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | claimed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | claimed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | claimed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | P2RX7 4659/4885GPR119 113/4885BCHE 339/4885 |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | P2RX7 4659/4885GPR119 113/4885BCHE 339/4885 |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | P2RX7 727/4885GPR119 1947/4885BCHE 656/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | P2RX7 1115/4885GPR119 2334/4885BCHE 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.